– USA, CA – Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of Tim Walbert to its Board of Directors.
“I have seen firsthand the insurmountable experience, passion and insight that Tim brings to leadership in the rare disease and broader pharmaceutical industry, building companies that deliver transformational treatments for patient communities while also generating value for shareholders,” said Board Chairman, Mike Grey.
The company also announced that Dr. Niall O’Donnell will step down from the Board of Directors at the 2023 AGM on June 12, 2023.
About Tim Walbert
Tim Walbert joins Mirum’s board following a 15-year tenure as president, CEO, and Chairman of the board of Horizon Therapeutics, which he built from inception to a leading rare disease company. Horizon recently announced its intent to be acquired by Amgen. Before joining Horizon, he served as president, CEO, and director of IDM Pharma Inc., a public biotechnology company which was acquired by Takeda America Holdings Inc. in June 2009. Before IDM Pharma, Mr. Walbert served as EVP, of commercial operations at NeoPharm Inc., a public biotechnology company. From 2001 to 2005, he served as divisional VP and GM, of immunology, at Abbott, now AbbVie, leading the global development and launch of the multi-indication biologic HUMIRA, and served as divisional VP, of global cardiovascular strategy. From 1998 to 2001, Mr. Walbert served as director, of CELEBREX North America, and arthritis team leader, of Asia Pacific, Latin America, and Canada, at G.D. Searle & Company. From 1991 to 1998, he also held sales and marketing roles with increasing responsibility at G.D. Searle, Merck & Co. Inc., and Wyeth.
Mr. Walbert currently serves on the board of Century Therapeutics, a public biotech company. He is also a member of the National Organization for Rare Disorders (NORD) Advisory Board, the Wall Street Journal CEO Council and serves on the Board of Trustees of Muhlenberg College. He previously served on the board of directors for Aurinia Pharmaceuticals, a public pharmaceutical company, from 2020 to 2022, Exicure, a public biotechnology company, from 2019 to 2022, Assertio, a public biopharma company, from 2014 to 2020, Raptor Pharmaceutical Corp., a public biotechnology company, from 2010 to 2014; XOMA Corporation, a public biotechnology company, from 2011 to 2017 and Sucampo Pharmaceuticals Inc., a public biopharmaceutical company, from 2015 to 2018. He is also a member of the Economic Club of Chicago, the Commercial Club of Chicago, and the Civic Committee of the Commercial Club of Chicago. Mr. Walbert was a previous board member of the Biotechnology Innovation Organization (BIO), the Pharmaceutical Research and Manufacturing Association (PhRMA), the Illinois Biotechnology Innovation Organization (iBIO), and World Business Chicago.
“This is a great time to join Mirum’s board as I believe the company is well-positioned for continued growth and success, with a talented and energetic team, exciting pipeline, and demonstrated achievements both in the clinic and commercially,” said Tim Walbert. “I look forward to contributing my experience in rare disease, in launching in multiple markets, helping Mirum propel to the next level, and ultimately benefiting pediatric and adult patients in need of transformative therapies to address their diseases.”
Mr. Walbert received a Bachelor of Arts in Business from Muhlenberg College.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases. Mirum’s approved medication is LIVMARLI (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome three months of age and older, and in Europe for the same indication in patients two months of age and older. Mirum has submitted LIVMARLI for approval in the U.S. (in cholestatic pruritus in PFIC for patients three months and older) and in Europe (in PFIC for patients two months and older).
Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. LIVMARLI, an oral ileal bile acid transporter inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the EMBARK Phase 2b clinical trial for patients with biliary atresia. In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC.
Mirum’s second investigational treatment, volixibat, an oral IBAT inhibitor, is being evaluated in two potentially registrational studies including the VISTAS Phase 2b clinical trial for adults with primary sclerosing cholangitis and the VANTAGE Phase 2b clinical trial for adults with primary biliary cholangitis.
Source: https://mirumpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
